Breaking News

Samsung BioLogics Expands Biomanufacturing Capabilities

Implements large scale N-1 perfusion for commercial application

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung BioLogics has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow (ATF) device to supply the 15,000L commercial production process in the Plant 3 facility at its manufacturing site in Songdo, S. Korea recently, reducing production time by up to 30% for the client.   With Samsung’s adoption of perfusion technology, clients may choose from a more diversified portfolio of manufacturing options. Perfusion is gaining broader biopharmaceutical application at small sc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters